Holen Sie sich die Stockscreener-App
4.78
6.27%
-0.32
Handel nachbörslich:
4.78
Schlusskurs vom Vortag:
$5.10
Offen:
$5.06
24-Stunden-Volumen:
852.22K
Relative Volume:
1.27
Marktkapitalisierung:
$299.75M
Einnahmen:
$91.06M
Nettoeinkommen (Verlust:
$-503.14M
KGV:
-0.4819
EPS:
-9.92
Netto-Cashflow:
$-424.74M
1W Leistung:
-24.13%
1M Leistung:
-36.86%
6M Leistung:
-59.15%
1J Leistung:
-75.05%
1-Tages-Spanne:
$4.735
$5.09
1-Wochen-Bereich:
$4.735
$6.28
52-Wochen-Spanne:
$4.735
$28.26
Sage Therapeutics Inc Stock (SAGE) Company Profile
Firmenname
Sage Therapeutics Inc
Sektor
Branche
Telefon
617-299-8380
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie SAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SAGE | 4.78 | 299.75M | 91.06M | -503.14M | -424.74M | -9.92 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-08-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Herabstufung | Goldman | Buy → Neutral |
| 2023-08-08 | Herabstufung | Needham | Buy → Hold |
| 2023-08-07 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-08-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-08-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-03-31 | Eingeleitet | Berenberg | Hold |
| 2021-11-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-04-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-02-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-02-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-01-22 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-01-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-09-11 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-08-10 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-04-08 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-28 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-06 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-12-05 | Bestätigt | Guggenheim | Buy |
| 2019-12-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-10-30 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-23 | Eingeleitet | Wedbush | Outperform |
| 2019-04-25 | Eingeleitet | Jefferies | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
BB Biotech AG's Strategic Acquisition of Sage Therapeutics Shares - GuruFocus.com
FMR LLC Adjusts Stake in Sage Therapeutics Inc - GuruFocus.com
Easterly Investment Partners LLC Sells 91,500 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com
Vanguard Group Inc's Recent Transaction in Sage Therapeutics Inc - GuruFocus.com
Objective long/short (SAGE) Report - Stock Traders Daily
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) sh - GuruFocus.com
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seekin - GuruFocus.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Pinnacle Associates Ltd. Has $1.22 Million Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Sage Therapeutics Inc Sued for Securities Law ViolationsConta - GuruFocus.com
Sage Therapeutics Reports Q3 Growth and Strategic Focus - TipRanks
Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Citeline News & Insights
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Sage Therapeutics CFO Kimi Iguchi resigns from position - XM
SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures - TipRanks
Cambridge biotech's layoffs will cut dozens of Mass. employees - The Business Journals
HC Wainwright Expects Weaker Earnings for Sage Therapeutics - MarketBeat
What is HC Wainwright's Estimate for SAGE FY2028 Earnings? - MarketBeat
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Call Transcript - Insider Monkey
Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler - Yahoo Finance
Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - MedCity News
Sage Therapeutics price target lowered to $14 from $25 at H.C. Wainwright - TipRanks
Scotiabank Lowers Sage Therapeutics (NASDAQ:SAGE) Price Target to $14.00 - MarketBeat
Sage Therapeutics price target lowered to $14 from $17 at Scotiabank - TipRanks
Sage Therapeutics' (SAGE) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Sage to sunset first postpartum depression drug, focus on Zurzuvae - The Business Journals
Sage Therapeutics (NASDAQ:SAGE) Issues Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates - MSN
Sage stock plunges 18% post-market following business update, earnings - MSN
Sage Therapeutics reports Q3 EPS ($1.53) , consensus ($1.53) - TipRanks
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates - Business Wire
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $13.76 Average PT from Analysts - MarketBeat
Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class ActionSAGE - The Malaysian Reserve
Deadline on Oct. 28th coming up in Lawsuit for Investors who lost - openPR
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.
DEADLINE ALERT for OM, SAGE, and SMCI: The Law Offices of - GlobeNewswire
FINAL SAGE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Sage Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
October 28, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SAGE - PR Newswire
FINAL REMINDER SAGE DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Sage Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - Stockhouse Publishing
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise - MSN
SAGE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
Finanzdaten der Sage Therapeutics Inc-Aktie (SAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):